Document resource
Background and Importance Current guidelines on acute coronary syndrome (ACS) recommend management that does not differ by patients’ sex. However, several studies show that, in clinical practice, prescribed discharge medications and dosages do vary by sex, with women being undertreated.Aim and Objectives To evaluate sex-related differences in discharge treatment following acute myocardial infarction.Material and Methods A retrospective observational study was conducted at a tertiary hospital, including patients diagnosed with acute myocardial infarction (ST-segment elevation myocardial infarction (STEMI) or Non-ST-segment Elevation Myocardial Infarction (NSTEMI)) from April-July 2025. Data on demographic, comorbidities, and discharge treatment were collected.Results One hundred ninety-seven patients were included, of these, 77.7% (n=153) were men and 22.3% (n=44) were women, with a median age of 63 years (range: 36-92) and 72 years (range: 44-93), respectively. The most frequent presentation in the study population was STEMI (56.9%), and 76.1% (n=150) of all patients were classified into Killip Class I on admission. Regarding cardiovascular risk factors, a higher proportion of men were current or former smokers compared to women (59.5% vs 43.2%; p<0.01), In contrast, hypertension (81.8% vs 54.2%; p<0.01) and chronic kidney disease (18.2% vs 7.2%; p<0.05) were more prevalent among women. Dyslipidemia (62%) and diabetes mellitus (28%) were the most common comorbidities, affecting both sexes similarly.Among discharge medications, aspirin (96.14% in men vs. 95.5% in women; p=1) and statins (98.7% vs. 95.5%; p=0.2) were prescribed similarly for both sexes. In contrast, P2Y12 inhibitors (iP2Y12) were more frequently prescribed to men than to women (92.2% vs. 79.5%; p<0.05). Despite having an indication for dual antiplatelet therapy (DAPT) according to the CRUSADE score (<30), women were treated less frequently than men (3.92% vs. 9.16%; p=1). Among the 12.2% of patients anticoagulated for atrial fibrillation, appropriate therapy (triple or dual therapy with iP2Y12 plus oral anticoagulant) was given to 93.8% of men vs 75% of women, p=0.3.Conclusion and Relevance Although some differences in discharge treatment between men and women were observed (eg, DAPT and anticoagulation), these were not statistically significant. The lack of significance may be related to the limited sample size. Larger studies are needed to confirm these findingsConflict of Interest No conflict of interest